SCHEMBL17465879

SCHEMBL17465879

COc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(c1ccccc1)CCC(=O)N2C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 5/20 0.75
PLK1 P53350 4/20 0.75
LRRK2 Q5S007 12/20 0.70
DCLK1 O15075 11/20 0.70
MAPK7 Q13164 10/20 0.70
PLK4 O00444 2/20 0.65
GAK O14976 2/20 0.65
STK33 Q9BYT3 1/20 0.65
PLK3 Q9H4B4 1/20 0.65
TNK2 Q07912 3/20 0.63
BRD4 O60885 2/20 0.61
TNK1 Q13470 2/20 0.61
DCLK2 Q8N568 2/20 0.61
PI4KA P42356 1/20 0.61
RPS6KA3 P51812 1/20 0.61
PTK2 Q05397 1/20 0.61
RPS6KA2 Q15349 1/20 0.61
RPS6KA1 Q15418 1/20 0.61
BRDT Q58F21 1/20 0.61
PI4KB Q9UBF8 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618543 0.93 TTK (0.76) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL617733 0.93 TTK (0.76) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL616568 0.91 LRRK2 (0.69) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL617073 0.86 PLK1 (1.00) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL3673701 0.85 RAD52 (0.62) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL619287 0.84 TTK (0.73) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL16065704 0.82 LRRK2 (0.74) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL618577 0.82 LRRK2 (1.00) LRRK2DCLK1MAPK7PLK4GAK
SCHEMBL1203122 0.81 RAD52 (0.77) TTKPLK1LRRK2DCLK1MAPK7
SCHEMBL10098681 0.80 MAPK7 (0.67) TTKPLK1LRRK2DCLK1MAPK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787461-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-29 US disclosed
US-20200071340-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-03-05 US disclosed
US-10457692-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-29 US disclosed
US-20190084998-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-03-21 US disclosed
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-01-29 US disclosed
US-20170283422-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2017-10-05 US disclosed
US-20170283422-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2017-10-05 US disclosed
US-9676792-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-06-13 US disclosed
US-9676792-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-06-13 US disclosed
US-20160024115-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2016-01-28 US disclosed
US-20160024115-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071340-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-20190084998-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-10787461-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-20170283422-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-10457692-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885
US-20160024115-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 TTK 31/4885PLK1 79/4885LRRK2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.